Lucia Notterpek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Lucia Notterpek has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Albert L. Misko
Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, USA
1 shared publication Amy Yazdanpour
Department of Neuroscience, McKnight Brain Institute, and §Department of Pharmacology and Therapeutics, College of Medicine, University of Florida, Gainesville, FL 32610; and ‡Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06520
1 shared publicationAndreas R. Tobler
1 shared publicationBrad S. Fletcher
Department of Neuroscience, McKnight Brain Institute, and §Department of Pharmacology and Therapeutics, College of Medicine, University of Florida, Gainesville, FL 32610; and ‡Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06520
1 shared publicationChristoph Rahner
Department of Neuroscience, McKnight Brain Institute, and §Department of Pharmacology and Therapeutics, College of Medicine, University of Florida, Gainesville, FL 32610; and ‡Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06520
1 shared publicationEric M. Shooter
1 shared publication
Latest Publications
- Open Access
- 19 November 2003
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 23 (33) , 10672-10680
Emerging Role for Autophagy in the Removal of Aggresomes in Schwann Cells
The presence of protein aggregates in the nervous system is associated with various pathological conditions, yet their contribution to disease mechanisms is poorly understood. One type of aggregate, the aggresome, accumulates misfolded proteins destined for degradation by the ubiquitin-proteasome pathway. Peripheral myelin protein 22 (PMP22) is a short-lived Schwann cell (SC) protein that forms aggresomes when the proteasome is inhibited or the protein is overexpressed. Duplication, deletion, or point mutations inPMP22are associated with a host of demyelinating peripheral neuropathies, suggesting that, for normal SC cell function, the levels of PMP22 must be tightly regulated. Therefore, we speculate that mutant, misfolded PMP22 might overload the proteasome and promote aggresome formation. To test this, sciatic nerves of Trembler J (TrJ) neuropathy mice carrying a leucine-to-proline mutation in PMP22 were studied. In TrJ neuropathy nerves, PMP22 has an extended half-life and forms aggresome-like structures that are surrounded by molecular chaperones and lysosomes. On the basis of these characteristics, we hypothesized that PMP22 aggresomes are transitory, linking the proteasomal and lysosomal protein degradation pathways. Here we show that Schwann cells have the ability to eliminate aggresomes by a mechanism that is enhanced when autophagy is activated and is primarily prevented when autophagy is inhibited. This mechanism of aggresome clearance is not unique to peripheral glia, because L fibroblasts were also capable of removing aggresomes. Our results provide evidence for the involvement of the proteasome pathway in TrJ neuropathy and for the role of autophagy in the clearance of aggresomes.
- 19 November 2003
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 23 (33) , 10672-10680
Open AccessEmerging Role for Autophagy in the Removal of Aggresomes in Schwann Cells
The presence of protein aggregates in the nervous system is associated with various pathological conditions, yet their contribution to disease mechanisms is poorly understood. One type of aggregate, the aggresome, accumulates misfolded proteins destined for degradation by the ubiquitin-proteasome pathway. Peripheral myelin protein 22 (PMP22) is a short-lived Schwann cell (SC) protein that forms aggresomes when the proteasome is inhibited or the protein is overexpressed. Duplication, deletion, or point mutations inPMP22are associated with a host of demyelinating peripheral neuropathies, suggesting that, for normal SC cell function, the levels of PMP22 must be tightly regulated. Therefore, we speculate that mutant, misfolded PMP22 might overload the proteasome and promote aggresome formation. To test this, sciatic nerves of Trembler J (TrJ) neuropathy mice carrying a leucine-to-proline mutation in PMP22 were studied. In TrJ neuropathy nerves, PMP22 has an extended half-life and forms aggresome-like structures that are surrounded by molecular chaperones and lysosomes. On the basis of these characteristics, we hypothesized that PMP22 aggresomes are transitory, linking the proteasomal and lysosomal protein degradation pathways. Here we show that Schwann cells have the ability to eliminate aggresomes by a mechanism that is enhanced when autophagy is activated and is primarily prevented when autophagy is inhibited. This mechanism of aggresome clearance is not unique to peripheral glia, because L fibroblasts were also capable of removing aggresomes. Our results provide evidence for the involvement of the proteasome pathway in TrJ neuropathy and for the role of autophagy in the clearance of aggresomes.
- 31 May 2003
- Published by Elsevier in Trends in Neurosciences
- Vol. 26 (5) , 232-234
Neurotrophins in myelination: a new role for a puzzling receptor
- 31 May 2003
- Published by Elsevier in Trends in Neurosciences
- Vol. 26 (5) , 232-234
Neurotrophins in myelination: a new role for a puzzling receptor
- 4 November 2002
- Published by Wiley in Journal of Neurochemistry
- Vol. 83 (4) , 885-894
Matrix metalloproteinase mediated degradation of basement membrane proteins in Trembler J neuropathy nerves
A single point mutation in peripheral myelin protein 22 (pmp22) of the Trembler‐J (TrJ) mouse models the human peripheral neuropathy, Charcot–Marie–Tooth disease type 1 A (CMT1A). An unexplored aspec...
- 4 November 2002
- Published by Wiley in Journal of Neurochemistry
- Vol. 83 (4) , 885-894
Matrix metalloproteinase mediated degradation of basement membrane proteins in Trembler J neuropathy nerves
A single point mutation in peripheral myelin protein 22 (pmp22) of the Trembler‐J (TrJ) mouse models the human peripheral neuropathy, Charcot–Marie–Tooth disease type 1 A (CMT1A). An unexplored aspec...
- Open Access
- 20 November 2001
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 98 (25) , 14404-14409
Peripheral myelin protein 22 is a constituent of intercellular junctions in epithelia
Alterations in peripheral myelin protein 22 (PMP22) gene expression are associated with a host of heritable demyelinating peripheral neuropathies, yet the function of the protein remains unknown. PMP22 expression is highest in myelinating Schwann cells of peripheral nerves; however, significant levels of PMP22 mRNAs can be detected in a variety of non-neural tissue, including epithelia. To date, PMP22 protein expression and localization in non-neural tissues have not been studied in detail. In adult rat liver and intestine, and cultured epithelial cells, we detected PMP22-like immunoreactivity associated with markers of the tight junctional complex, including zonula occludens 1 (ZO-1) and occludin. Upon disruption of intercellular contacts, PMP22 was internalized into vesicles that were immunoreactive for both anti-occludin and anti-PMP22 antibodies. Nonionic detergent extraction of cultured epithelial cells did not solubilize PMP22, as the majority of the protein remained in the detergent insoluble fraction, as did ZO-1 and occludin. We also observed the targeting of exogenous myc-tagged PMP22 to apical cell junctions in polarized epithelia and to anti-ZO-1 antibody immunoreactive cell contacts of L fibroblasts. These studies support a role for PMP22 at intercellular junctions of epithelia and may indicate a similar function in myelinating Schwann cells. Furthermore, our findings could provide an explanation for certain phenotypes of PMP22 neuropathy mice that cannot be accounted for by dysmyelination.
- 20 November 2001
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 98 (25) , 14404-14409
Open AccessPeripheral myelin protein 22 is a constituent of intercellular junctions in epithelia
Alterations in peripheral myelin protein 22 (PMP22) gene expression are associated with a host of heritable demyelinating peripheral neuropathies, yet the function of the protein remains unknown. PMP22 expression is highest in myelinating Schwann cells of peripheral nerves; however, significant levels of PMP22 mRNAs can be detected in a variety of non-neural tissue, including epithelia. To date, PMP22 protein expression and localization in non-neural tissues have not been studied in detail. In adult rat liver and intestine, and cultured epithelial cells, we detected PMP22-like immunoreactivity associated with markers of the tight junctional complex, including zonula occludens 1 (ZO-1) and occludin. Upon disruption of intercellular contacts, PMP22 was internalized into vesicles that were immunoreactive for both anti-occludin and anti-PMP22 antibodies. Nonionic detergent extraction of cultured epithelial cells did not solubilize PMP22, as the majority of the protein remained in the detergent insoluble fraction, as did ZO-1 and occludin. We also observed the targeting of exogenous myc-tagged PMP22 to apical cell junctions in polarized epithelia and to anti-ZO-1 antibody immunoreactive cell contacts of L fibroblasts. These studies support a role for PMP22 at intercellular junctions of epithelia and may indicate a similar function in myelinating Schwann cells. Furthermore, our findings could provide an explanation for certain phenotypes of PMP22 neuropathy mice that cannot be accounted for by dysmyelination.
- Open Access
- 1 October 1999
- Published by Elsevier in Neurobiology of Disease
- Vol. 6 (5) , 450-460
PMP22 Accumulation in Aggresomes: Implications for CMT1A Pathology
- 1 October 1999
- Published by Elsevier in Neurobiology of Disease
- Vol. 6 (5) , 450-460
Open AccessPMP22 Accumulation in Aggresomes: Implications for CMT1A Pathology